|Day Low/High||53.86 / 54.81|
|52 Wk Low/High||49.96 / 70.05|
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty cents ($0.
Bristol-Myers Squibb Company (NYSE: BMY) today confirmed that 31 abstracts demonstrating The Company's immunoscience-research focus as well as how ORENCIA ® (abatacept) therapy may impact diverse patient subgroups will be presented at the Annual European...
Bristol-Myers Squibb Company (NYSE: BMY) will take part in Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018, in Rancho Palos Verdes, CA.
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2018 on Thursday, July 26, 2018.
Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
Nektar Therapeutics shares got destroyed on Monday. Here is why.
Bristol-Myers Squibb Company (NYSE:BMY) today announced updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence...
Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S.
Bristol-Myers Squibb Company (NYSE:BMY) today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC) treated with the Immuno-Oncology combination...
Bristol-Myers Squibb Company (NYSE:BMY) will hold an investor event on Monday, June 4, 2018 at 8:30 p.
President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.
Options spreads aren't tradable with some small biotechs, making shares the only way to play.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that data from over 70 Company-sponsored studies and collaborations evaluating its oncology compounds across more than 20 types of cancer will be featured at the American Society of Clinical Oncology...
Jim Cramer weighs in on Consolidated Edison, Clorox, Chesapeake Energy, Adaptimmune Therapeutics, Icahn Enterprises, Bristol-Meyers Squibb and more.
Get ahead of the naysayers, says Jim Cramer. FANG and other tech leaders have gone cold, but they're not dead yet.
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the UBS 2018 Global Healthcare Conference on Tuesday, May 22, 2018, in New York.
President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated a type II variation application for the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for treatment in adult patients with first-line...
Bristol-Myers Squibb (NYSE:BMY) and Flatiron Health, a market leader in oncology-specific electronic health record software and the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, expanded their...
KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.
U.S. stock futures suggest Wall Street will open with modest gains on Thursday; Facebook posts a blowout quarter; Amazon and Microsoft to report earnings; Ford is no longer a car company.
Rising oil prices, surging bond yields and mixed earnings forecasts have stalled overnight gains for global stocks and pulled U.S. equity futures into the red ahead of another hectic slate of corporate reports.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2018 which were highlighted by strong sales for Opdivo , Eliquis , and Orencia, important regulatory progress in Immuno-Oncology and strategic business...
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved an every four-week (Q4W) Opdivo (nivolumab) monotherapy dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced...
Let's look at the charts this afternoon.
Jim Cramer highlights Wendy's, Spirit AeroSystems, Dunkin Brands, Bristol-Meyers Squibb, Take-Two Interactive and more.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.